Chong Kun Dang Pharmaceutical
Chong Kun Dang Pharmaceutical
Explore linked clinical trials.13 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Korean Study on Safety and Effectiveness of OAD Triple Therapy in Type 2 Diabetes | Nutritional and Metabolic Diseases, diabetes mellitus, endocrine system disorder, glucose metabolism disease, metabolic disease, type 2 diabetes mellitus | Recruiting | Not stated | 2026-09-30 | NCT06838286 | |
| A Phase 3 Study to Evaluate the Safety and Efficacy of CKD-843 in Male Patients With Androgenetic Alopecia | Pathological Conditions, Anatomical, Pathological Conditions, Signs and Symptoms, Skin and Connective Tissue Diseases, alopecia, androgenetic alopecia, disorder of pilosebaceous unit, hypotrichosis, skin disorder | Recruiting | Phase 3 | 2026-09-03 | NCT06916793 | |
| Clinical Study to Evaluate the Pharmacokinetics and Safety of CKD-339 in Healthy Volunteers | cardiovascular disorder, hypertensive disorder, vascular disorder | Not yet recruiting | Phase 1 | 2026-08-06 | NCT07748702 | |
| Comparison of the Incidence of Major Cardiovascular Events Between the Combination of Percutaneous Intervention and Optimal Drug Therapy and the Optimal Drug Therapy Alone in Patients With Chronic Coronary Syndrome | Chronic Coronary Syndrome | Not yet recruiting | Not applicable | 2026-06-12 | NCT07577518 | |
| A First-in-Human Study of CKD-703 in Advanced Solid Tumors and Non-Small Cell Lung Cancer | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Recruiting | Phase 1 / Phase 2 | 2026-04-27 | NCT07439094 | |
| Study of CKD-215 and D215 in Adults With BRCA-mutated Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | Adnexal Diseases, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, endocrine system disorder, female reproductive system disorder, female reproductive system neoplasm, gonadal disorder, malignant endocrine neoplasm, neoplasm, ovarian cancer, ovarian disorder | Not yet recruiting | Phase 1 | 2026-04-15 | NCT07532148 | |
| Study to Compare the Efficacy and Safety After Conversion to RaparoBell® or My-Rept® in Kidney Transplant Patients | Kidney Transplantation | Active, not recruiting | Phase 4 | 2026-02-17 | NCT05193565 | |
| Phase Ia/Ib Study of CKD-512 Alone and in Combination With Pembrolizumab in Subjects With Advanced or Metastatic Solid Tumors | Advanced Solid Tumors; Metastatic Solid Tumors | Recruiting | Phase 1 | 2026-02-02 | NCT07215637 | |
| Evaluate the Efficacy and Safety of Empagliflozin or Glimepiride Combination Therapy in Type 2 Diabetes Mellitus Patients | Nutritional and Metabolic Diseases, diabetes mellitus, endocrine system disorder, glucose metabolism disease, metabolic disease, type 2 diabetes mellitus | Not yet recruiting | Phase 4 | 2026-01-26 | NCT07365358 | |
| A Study to Compare the Pharmacokinetics, Pharmacodynamic, Immunogenicity, and Safety of CKD-706 With US-Dupixent®, and EU-Dupixent® in Healthy Adult Participants. | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Hypersensitivity, Immediate, Skin Diseases, Eczematous, Skin and Connective Tissue Diseases, atopic eczema, dermatitis, hereditary disease, hereditary skin disorder, immune system disorder, skin disorder | Recruiting | Phase 1 | 2026-01-23 | NCT07358156 | |
| Pharmacokinetic, Safety, Tolerability, and Immunogenicity Comparison of CKD-704 (Risankizumab Biosimilar), With EU-approved Skyrizi®, and US-licensed Skyrizi® in Healthy Adult Participants | Skin Diseases, Papulosquamous, Skin and Connective Tissue Diseases, psoriasis, skin disorder | Recruiting | Phase 1 | 2025-12-19 | NCT07258745 | |
| Phase 3 Trial to Evaluate the Efficacy and Safety of CKD-202A | cardiovascular disorder, essential hypertension, hypertensive disorder, vascular disorder | Recruiting | Phase 3 | 2025-12-11 | NCT06643819 | |
| Optimize Immunosuppressive Therapy Using Everolimus and Low-dose Calcineurin Inhibitors in Heart Transplant Patients in Korea | Heart Transplant | Not yet recruiting | Phase 4 | 2025-04-24 | NCT06942156 |